[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"grants-domain-drug-discovery":3},{"grants":4,"total":287,"limit":288,"offset":289},[5,27,37,56,68,82,88,103,117,129,145,158,171,182,266,279,284],{"id":6,"name":7,"funder":8,"budget":9,"budget_min_eur":10,"budget_max_eur":11,"budget_high_priority":12,"duration":13,"deadline":14,"deadline_note":15,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":17,"link":18,"first_seen":19,"last_updated":13,"update_note":13,"status":20,"stages":21,"call_frequency":22,"next_call_expected":13,"source_url":18,"created_at":23,"updated_at":23,"eligible_countries":24,"seo_summary":13,"seo_summary_hash":13,"description":26},"kwf-lead4life-ppp-call-lead-212-radiopharmaceuticals-2026-05","Lead4Life PPP Call — Lead-212 Radiopharmaceuticals","KWF","€500k–€2M per project; total €5M",500000,2000000,true,null,"2026-05-05T00:00:00.000Z","Call opens 5 May 2026; submission deadline not yet specified",false,"Required — public-private partnership (PPP) collaboration required","https:\u002F\u002Fwww.kwf.nl\u002Fen\u002Fforresearchers\u002Ffunding\u002Flead4life","2026-04-27T00:00:00.000Z","open","Single stage (open competitive selection via KWF GMS)","One-off","2026-04-27T13:58:44.162Z",[25],"NL","PPP call for projects strengthening Pb-212 production\u002Fsupply chain or enabling technologies for clinical application of Pb-212-based radiopharmaceuticals. Proposals must involve public-private collaboration and be submitted through KWF GMS; projects are embedded in a national TRT innovation network. Clinical trials and full therapeutic product development are out of scope.",{"id":28,"name":29,"funder":8,"budget":30,"budget_min_eur":10,"budget_max_eur":11,"budget_high_priority":12,"duration":13,"deadline":14,"deadline_note":15,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":31,"link":18,"first_seen":32,"last_updated":13,"update_note":13,"status":20,"stages":33,"call_frequency":22,"next_call_expected":13,"source_url":18,"created_at":34,"updated_at":34,"eligible_countries":35,"seo_summary":13,"seo_summary_hash":13,"description":36},"kwf-lead4life-ppp-call-lead-212-production-supply-chai-2026-05","Lead4Life PPP Call — Lead-212 Production & Supply Chain and Enabling Technologies","€500k–€2M per project; total budget €5M","Required — public-private partnership (PPP) with industry co-funding (40–60% matching)","2026-04-29T00:00:00.000Z","Single stage (open competitive call via KWF GMS)","2026-04-29T04:20:58.422Z",[25],"PPP call for projects strengthening Pb-212 production\u002Fsupply chain or enabling technologies for clinical application of Pb-212-based radiopharmaceuticals. Proposals must involve public-private collaboration with 40–60% industry co-funding, be submitted through KWF GMS, and align with Lead4Life governance and national TRT network. Clinical trials and full therapeutic product development are out of scope.",{"id":38,"name":39,"funder":40,"budget":41,"budget_min_eur":42,"budget_max_eur":43,"budget_high_priority":16,"duration":44,"deadline":45,"deadline_note":46,"trl":47,"relevance":13,"why_relevant":13,"early_career":16,"consortium":48,"link":49,"first_seen":50,"last_updated":50,"update_note":13,"status":20,"stages":51,"call_frequency":52,"next_call_expected":53,"source_url":49,"created_at":54,"updated_at":55,"eligible_countries":13,"seo_summary":13,"seo_summary_hash":13,"description":13},"snsf-clinical-trials-2026","SNSF Investigator Initiated Clinical Trials 2026","Swiss National Science Foundation","Up to CHF 2 million (~€2.1M)",200000,2100000,"3-5 years","2026-05-26T00:00:00.000Z","Submission deadline May 26, 2026 at 17:00 CEST.","5-7","Required — consortium","https:\u002F\u002Fwww.snf.ch\u002Fen\u002FLlLsqrrZVo4EqWui\u002Fpage\u002Fopen-calls","2026-03-23T00:00:00.000Z","full-proposal","annual","2027-05","2026-03-23T12:33:13.113Z","2026-03-23T13:26:38.500Z",{"id":57,"name":58,"funder":59,"budget":13,"budget_min_eur":13,"budget_max_eur":13,"budget_high_priority":16,"duration":13,"deadline":45,"deadline_note":60,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":13,"link":61,"first_seen":62,"last_updated":13,"update_note":13,"status":20,"stages":13,"call_frequency":63,"next_call_expected":13,"source_url":61,"created_at":64,"updated_at":64,"eligible_countries":65,"seo_summary":13,"seo_summary_hash":13,"description":67},"snsf-call-for-proposals-investigator-initiated-clinical-2026-05","Call for proposals – Investigator initiated clinical trials 2026","SNSF","17:00 CEST","https:\u002F\u002Fwww.snf.ch\u002Fen\u002FJQwY78sxGqxYi2LJ\u002Fnews\u002Fcall-for-proposals-investigator-initiated-clinical-trials-2026","2026-04-18T00:00:00.000Z","Annual","2026-04-18T16:12:00.546Z",[66],"CH","Supports investigator-initiated clinical trials (RCTs and other interventional studies) conducted by researchers at Swiss institutions. Clinical trial \u002F RCT focus; patient-sample involvement expected.",{"id":69,"name":70,"funder":8,"budget":13,"budget_min_eur":13,"budget_max_eur":13,"budget_high_priority":16,"duration":13,"deadline":71,"deadline_note":72,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":73,"link":74,"first_seen":32,"last_updated":13,"update_note":13,"status":20,"stages":75,"call_frequency":22,"next_call_expected":13,"source_url":74,"created_at":34,"updated_at":34,"eligible_countries":76,"seo_summary":13,"seo_summary_hash":13,"description":81},"kwf-inter-local-international-funding-call-for-local-t-2026-06","INTER-LOCAL: International Funding Call for Local Treatment Strategies in Rare and Hard-to-Treat Cancers","2026-06-18T00:00:00.000Z","Full proposal deadline: 18 June 2026, 12:00 noon CEST","Required — partners from at least 3 of 5 funding countries (Belgium, Netherlands, Spain, Norway, Sweden)","https:\u002F\u002Fwww.kwf.nl\u002Fen\u002Fforresearchers\u002Ffunding\u002Finter-local","2-stage: pre-proposal → full proposal",[77,25,78,79,80],"BE","ES","NO","SE","Supports late-phase (phase 2\u002F3) international clinical trials focused on radiotherapy or surgery as core experimental interventions for rare cancers (incidence \u003C6\u002F100,000\u002Fyear) and\u002For hard-to-treat cancers (5-year survival \u003C25%). Proposals must include partners from at least 3 of the 5 funding countries and demonstrate strong rationale for international collaboration, patient involvement, and quality-of-life assessment.",{"id":83,"name":84,"funder":8,"budget":13,"budget_min_eur":13,"budget_max_eur":13,"budget_high_priority":16,"duration":13,"deadline":71,"deadline_note":85,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":73,"link":74,"first_seen":19,"last_updated":13,"update_note":13,"status":20,"stages":75,"call_frequency":22,"next_call_expected":13,"source_url":74,"created_at":23,"updated_at":23,"eligible_countries":86,"seo_summary":13,"seo_summary_hash":13,"description":87},"kwf-inter-local-international-funding-call-for-clinica-2026-06","INTER-LOCAL: International Funding Call for Clinical Research into Local Treatment Strategies for Rare and Hard-to-Treat Cancers","Full proposal closure: 18 June 2026, 12:00 noon CEST",[77,25,78,79,80],"Supports late-phase (phase 2\u002F3) international clinical trials focused on radiotherapy or surgery as core experimental interventions for rare cancers (incidence \u003C6\u002F100,000\u002Fyear) and\u002For hard-to-treat cancers (5-year survival \u003C25%). Requires partners from at least 3 of 5 funding countries; clinical-trial focus with mandatory patient involvement and quality-of-life assessment plans.",{"id":89,"name":90,"funder":91,"budget":92,"budget_min_eur":13,"budget_max_eur":93,"budget_high_priority":16,"duration":94,"deadline":95,"deadline_note":96,"trl":97,"relevance":13,"why_relevant":13,"early_career":16,"consortium":98,"link":99,"first_seen":19,"last_updated":32,"update_note":13,"status":20,"stages":100,"call_frequency":13,"next_call_expected":13,"source_url":99,"created_at":23,"updated_at":34,"eligible_countries":101,"seo_summary":13,"seo_summary_hash":13,"description":102},"kwf-kankerbestrijding-boost-bridging-obstacles-for-optimal-model-use-via-2026-07","BOOST (Bridging Obstacles for Optimal model use via Shared Technical expertise)","KWF Kankerbestrijding","~€150,000 per project",150000,"6-24 months","2026-07-01T00:00:00.000Z","Deadline inferred from reference to 1 July 2026 cut-off; participating institutes not yet registered must submit registration request at least 6 weeks prior to closing date","3+","No","https:\u002F\u002Fwww.kwf.nl\u002Fen\u002Fforresearchers\u002Ffunding\u002Fboost","Single stage: full-proposal only",[25],"Open to researchers with an ongoing or recently finished KWF drug research project (start ≥6 months ago, end ≤1.5 years before 1 July 2026). Funds access to clinically relevant preclinical models, technologies and expertise (e.g. NAMs, PDX, organoids, CROs) to improve translational value. Dutch institutions only; commercial partner involvement requires a letter of intent.",{"id":104,"name":105,"funder":8,"budget":106,"budget_min_eur":107,"budget_max_eur":108,"budget_high_priority":12,"duration":13,"deadline":109,"deadline_note":110,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":13,"link":111,"first_seen":112,"last_updated":32,"update_note":13,"status":20,"stages":113,"call_frequency":63,"next_call_expected":13,"source_url":111,"created_at":114,"updated_at":34,"eligible_countries":115,"seo_summary":13,"seo_summary_hash":13,"description":116},"kwf-pipeline-2027-2026-07","Pipeline-2027","€1M–€2.5M (Phase I\u002FI-II); €1M–€5M (Phase II\u002FIII)",1000000,5000000,"2026-07-07T00:00:00.000Z","Pre-proposal deadline: 12:00 noon. Full proposal deadline: 8 December 2026 (12:00 noon)","https:\u002F\u002Fwww.kwf.nl\u002Fen\u002Fforresearchers\u002Ffunding\u002Fpipeline","2026-04-12T00:00:00.000Z","2-stage: pre-proposal → full proposal (by invitation only)","2026-04-12T04:22:44.300Z",[25],"Supports academic-led clinical trials (Phase I–III) for new investigational medicinal products targeting cancer with unmet medical needs. Lead institute must be in the Netherlands; public participating parties must be in Europe. Patient involvement required; public-private partnerships allowed. Proposals must be in English.",{"id":118,"name":119,"funder":8,"budget":13,"budget_min_eur":13,"budget_max_eur":13,"budget_high_priority":16,"duration":13,"deadline":109,"deadline_note":120,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":98,"link":121,"first_seen":122,"last_updated":123,"update_note":13,"status":20,"stages":124,"call_frequency":63,"next_call_expected":13,"source_url":121,"created_at":125,"updated_at":126,"eligible_countries":127,"seo_summary":13,"seo_summary_hash":13,"description":128},"kwf-boost-2026","Boost-2026","12:00 noon","https:\u002F\u002Fwww.kwf.nl\u002Fen\u002Fforresearchers\u002Ffunding","2026-03-25T00:00:00.000Z","2026-04-19T00:00:00.000Z","Single stage","2026-03-25T03:15:50.757Z","2026-04-19T04:35:49.971Z",[25],"Add-on funding exclusively for ongoing or recently completed KWF projects to strengthen translational relevance of oncology drug development. Supports training, implementation, and validation of advanced preclinical models; outsourcing to academic service providers or CROs is allowed.",{"id":130,"name":131,"funder":132,"budget":133,"budget_min_eur":13,"budget_max_eur":134,"budget_high_priority":16,"duration":135,"deadline":136,"deadline_note":137,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":98,"link":138,"first_seen":62,"last_updated":19,"update_note":13,"status":20,"stages":139,"call_frequency":63,"next_call_expected":13,"source_url":138,"created_at":140,"updated_at":141,"eligible_countries":142,"seo_summary":13,"seo_summary_hash":13,"description":144},"cancer-research-uk-discovery-programme-foundation-award-2026-09","Discovery Programme Foundation Award","Cancer Research UK","Up to £1.5m",1900000,"6 years","2026-09-29T00:00:00.000Z","Outline application deadline; applications reviewed twice per year","https:\u002F\u002Fwww.cancerresearchuk.org\u002Ffunding-for-researchers\u002Four-funding-schemes\u002Fdiscovery-programme-foundation-awards","2-stage: outline application → full application + interview","2026-04-18T16:12:03.724Z","2026-04-27T14:06:55.284Z",[143],"GB","For mid-career researchers at UK universities, medical schools, hospitals or research institutions seeking to develop independent research programmes in cancer biology. Applicants must hold a salaried independent position funded by a Higher Education Funding Council, NHS or equivalent. Clinical trials, drug discovery as sole function, and early detection\u002Fprevention are excluded. Closed scheme requiring prior contact with CRUK before applying.",{"id":146,"name":147,"funder":148,"budget":149,"budget_min_eur":13,"budget_max_eur":150,"budget_high_priority":16,"duration":151,"deadline":152,"deadline_note":153,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":98,"link":154,"first_seen":122,"last_updated":123,"update_note":13,"status":20,"stages":155,"call_frequency":63,"next_call_expected":13,"source_url":154,"created_at":125,"updated_at":126,"eligible_countries":156,"seo_summary":13,"seo_summary_hash":13,"description":157},"nwo-open-technology-programme-2026","Open Technology Programme 2026","NWO","Up to €950k (up to €1,050k for investment-heavy projects)",1050000,"Up to 6 years","2026-12-11T00:00:00.000Z","Continuous submission from 12 January 2026 until 11 December 2026, subject to grant ceiling or maximum number of applications","https:\u002F\u002Fwww.nwo.nl\u002Fen\u002Fcalls\u002Fopen-technology-programme-2026","Single stage (jury-based assessment in batches of 18 applications in order of receipt)",[25],"Open to researchers with a tenured or tenure-track position at Dutch universities, UMCs, KNAW\u002FNWO institutes, and select other Dutch research organisations. Supports free and independent technology research with societal\u002Fscientific impact; requires a user committee of at least four knowledge users. Not intended for proposals predominantly focused on investments, contract research, or clinical trials.",{"id":159,"name":160,"funder":161,"budget":13,"budget_min_eur":13,"budget_max_eur":13,"budget_high_priority":16,"duration":13,"deadline":13,"deadline_note":162,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":13,"link":163,"first_seen":123,"last_updated":19,"update_note":13,"status":20,"stages":164,"call_frequency":165,"next_call_expected":13,"source_url":163,"created_at":166,"updated_at":167,"eligible_countries":168,"seo_summary":13,"seo_summary_hash":13,"description":170},"deutsche-krebshilfe-krebs-therapiestudien-investigator-initiated-trial-2026","Krebs-Therapiestudien (Investigator Initiated Trials)","Deutsche Krebshilfe","No deadline — applications accepted at any time","https:\u002F\u002Fwww.krebshilfe.de\u002Fforschen\u002Ffoerderung\u002Ffoerderprogramme\u002Fkrebstherapiestudien\u002F","2-stage: Part I (short application) → Part II (full application, by invitation only)","Continuous","2026-04-19T04:35:51.612Z","2026-04-27T13:58:46.312Z",[169],"DE","Supports non-commercial, investigator-initiated cancer therapy trials (Investigator Initiated Trials). Applicants must submit a Part I short application; Part II is only submitted upon invitation by Deutsche Krebshilfe. Clinical trial focus with patient recruitment requirements; proposals must be in German.",{"id":172,"name":173,"funder":174,"budget":175,"budget_min_eur":13,"budget_max_eur":13,"budget_high_priority":16,"duration":176,"deadline":13,"deadline_note":177,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":178,"link":179,"first_seen":180,"last_updated":13,"update_note":13,"status":20,"stages":124,"call_frequency":22,"next_call_expected":13,"source_url":179,"created_at":181,"updated_at":181,"eligible_countries":13,"seo_summary":13,"seo_summary_hash":13,"description":13},"wellcome-infectious-disease-clinical-trial-development-awar-2026","Infectious Disease Clinical Trial Development Award","Wellcome","Up to £200,000 per award","Up to 24 months","Application stage dates to be calculated","Required — minimum 2 applicants","https:\u002F\u002Fwellcome.org\u002Fresearch-funding\u002Fschemes\u002Finfectious-disease-clinical-trial-development-award","2026-04-02T00:00:00.000Z","2026-04-02T08:42:41.887Z",{"id":183,"name":184,"funder":174,"budget":185,"budget_min_eur":186,"budget_max_eur":187,"budget_high_priority":12,"duration":188,"deadline":13,"deadline_note":189,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":190,"link":191,"first_seen":180,"last_updated":13,"update_note":13,"status":20,"stages":13,"call_frequency":22,"next_call_expected":13,"source_url":191,"created_at":181,"updated_at":181,"eligible_countries":192,"seo_summary":13,"seo_summary_hash":13,"description":13},"wellcome-infectious-disease-clinical-trial-award-optimising-2026","Infectious Disease Clinical Trial Award: Optimising Interventions Impact","£1,000,000–£8,000,000 per award",1190000,9520000,"3 to 5 years","Calculating next key date","Required — at least 1 coapplicant","https:\u002F\u002Fwellcome.org\u002Fresearch-funding\u002Fschemes\u002Finfectious-disease-clinical-trial-award-optimising-interventions-impact",[193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265],"BF","BJ","BW","CD","CF","CG","CI","CM","CV","DJ","DZ","EG","EH","ER","ET","GA","GH","GM","GN","GQ","GW","KE","KM","LR","LS","LY","MA","MG","ML","MR","MU","MW","MZ","NA","NE","NG","RE","RW","SC","SD","SL","SN","SO","SS","ST","SZ","TD","TG","TN","TZ","UG","ZA","ZM","ZW","AF","BD","BT","IN","LK","MV","NP","PK","BN","KH","ID","LA","MM","MY","PH","SG","TH","TL","VN",{"id":267,"name":268,"funder":174,"budget":269,"budget_min_eur":270,"budget_max_eur":271,"budget_high_priority":12,"duration":272,"deadline":13,"deadline_note":273,"trl":274,"relevance":13,"why_relevant":13,"early_career":16,"consortium":98,"link":179,"first_seen":275,"last_updated":50,"update_note":13,"status":20,"stages":276,"call_frequency":165,"next_call_expected":13,"source_url":179,"created_at":277,"updated_at":278,"eligible_countries":13,"seo_summary":13,"seo_summary_hash":13,"description":13},"wellcome-infectious-disease-trial-dev","Wellcome Infectious Disease Clinical Trial Development Award","Up to £3M",1500000,3500000,"Up to 5 years","Rolling. For clinical trial development in infectious disease.","Clinical","2026-03-22T00:00:00.000Z","2-stage","2026-03-22T19:56:24.910Z","2026-03-23T13:26:30.031Z",{"id":280,"name":173,"funder":174,"budget":175,"budget_min_eur":13,"budget_max_eur":13,"budget_high_priority":16,"duration":176,"deadline":13,"deadline_note":281,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":178,"link":179,"first_seen":275,"last_updated":13,"update_note":13,"status":20,"stages":124,"call_frequency":22,"next_call_expected":13,"source_url":179,"created_at":282,"updated_at":282,"eligible_countries":283,"seo_summary":13,"seo_summary_hash":13,"description":13},"wellcome-trust-infectious-disease-clinical-trial-development-awar-2026","Application deadline not specified on page","2026-03-22T16:38:54.889Z",[195,209,214,224,228,230,242,243,244,245,248,250,251,253,254,255,256,257,258,260,259,261,262,263,265],{"id":285,"name":184,"funder":174,"budget":185,"budget_min_eur":186,"budget_max_eur":187,"budget_high_priority":12,"duration":44,"deadline":13,"deadline_note":189,"trl":13,"relevance":13,"why_relevant":13,"early_career":16,"consortium":190,"link":191,"first_seen":275,"last_updated":13,"update_note":13,"status":20,"stages":124,"call_frequency":22,"next_call_expected":13,"source_url":191,"created_at":286,"updated_at":286,"eligible_countries":13,"seo_summary":13,"seo_summary_hash":13,"description":13},"wellcome-trust-infectious-disease-clinical-trial-award-optimising-2026","2026-03-22T16:38:56.516Z",17,50,0]